2021 was a particularly important year in the history of our Group, not only for the outstanding results delivered in terms of revenues, profitability, cash flow generation and profit, but also for the acquisition of Luminex Corporation -the largest ever made by DiaSorin- completed in July.
Against this challenging backdrop marked by the COVID-19 pandemic, our Company remained true to the desire to expand our technology and commercial offering, both through the ongoing commitment of our researchers, and thanks to partnerships with innovative in vitro diagnostics companies.
The strengthening of DiaSorin's role as a diagnostic specialist and a global player was a significant input towards the Luminex acquisition, a leading company in the fields of multiplexing molecular diagnostics and Life Science. This event marked the beginning of DiaSorin’s new business cycle that was presented in December during the Investor Day 2021 along with several projects, which the Management is very proud of, and that will drive the Group towards an even stronger growth in the next 4 years.
- the “Direct Amplification Disc (DAD)” consumable for fast, “on demand” results, also at laboratories with low-volume testing, or during urgent procedures such as, for example, the identification of patients to be isolated in hospitals;
- the “Universal Disc (UD)” for routine, screening or high-throughput results
The Aries® platform allows laboratories to control every aspect of the sample-to-answer testing process and it allows multiple sample types and up to 12 different IVD assays.
ARIES® cassettes contain all of the reagents needed to run PCR testing on a sample. All the test phases, including extraction and purification do not require external control or equipment. ARIES® cassettes are also color coded and can be stored at room temperature
The VERIGENE® system is scalable, allowing throughput customization to meet the size and testing demands of each laboratory. Panels available on the VERIGENE® platform are designed to target infections in the bloodstream, respiratory tract, and gastrointestinal tract. VERIGENE® tests cartridges are single-use and each test cartridge is designed for multiplex analysis of one patient sample.
The xMAP INTELLIFLEX® platform features a dual reporter functionality thanks to which the user can acquire data on two parameters per target protein or nucleic acid, saving time and generating higher volumes of data from a smaller number of samples..
Development of new products
LIAISON® SARS-CoV-2 TrimericS IgG
A new quantitative serology test for determination of IgG antibodies against SARS-CoV-2 in patients that were either subject to natural infections or vaccinated against COVID-19. It’s available in countries accepting the CE Mark and approved in the U.S. through Emergency Use Authorization.
LIAISON® Lyme IgM AND LIAISON® Lyme IgG
Test for the identification of IgG and IgM antibodies against Borrelia burgdorferi, a pathogen responsible for Lyme Borreliosis (or Lyme disease), available both in countries accepting the CE Mark and in the U.S.
LIAISON® SARS-CoV-2 Ag
Antigen test to identify SARS-CoV-2 in symptomatic patients, available in countries accepting the CE Mark and approved in the U.S. through Emergency Use Authorization.
Test developed in partnership with QIAGEN for the early diagnosis of Lyme Borreliosis infection, available on LIAISON® platforms in countries accepting the CE mark.
LIAISON® IQ and LIAISON® Quick Detect COVID TrimericS Ab
Point-of-Care immunodiagnostic platform, developed in collaboration with Lumos Diagnostics, and its first test for the detection of specific IgG antibodies against SARS-CoV-2 from a capillary blood sample using lateral flow technology. Both products are available in countries accepting CE mark.
LIAISON® Murex AntiHEV IgG & IgM
Test for the diagnosis of Hepatitis E on LIAISON® platforms, available in all countries accepting CE mark. It is the first CLIA fully automated high-throughput solution launched for the diagnosis of Hepatitis E (HEV).
LIAISON® MeMed BV®
Test to differentiate accurately between bacterial and viral infections.This new test was developed in collaboration with the Israeli company MeMed and launched in countries accepting the CE mark.
Simplexa™ SARS-CoV-2 Variants Direct (Research Use Only)
Research Use Only test for the detection of mutations of the SARS-CoV-2 virus, designed to simplify the monitoring of the spread of the variants of concern.
Simplexa™ COVID-19 & Flu A/B
Test that identifies and distinguishes a broad spectrum of mutations of both the SARS-CoV-2 virus and flu A and B.
Compact, flow-based multiplex platform that combines the performance of xMAP® technology with advanced features to improve performance, support innovation and test development, and simplify the user experience. It is the only multiplex platform that combines low-plex and high-plex capabilities, speed of execution with reliable results and the ability to simultaneously acquire data for two parameters per analyte.